AstraZeneca: Annual Report 2015 (AstraZeneca) - Mar 26, 2016 - Discontinuation in solid tumors due to strategic reason; Discontinuation of MEDI6469 + rituximab in solid tumors due to strategic reason; Discontinuation of MEDI6469 + tremelimumab in solid tumors due to strategic reason
Discontinued • Biosimilar • Gastrointestinal Cancer • Non Small Cell Lung Cancer • Oncology
|